Introduction {#s1}
============

Phagocytosis of invading microorganisms by specialized cells such as macrophages and neutrophils is a key component of the immune innate response. Phagocytosis is also a fundamental process for removal of cells undergoing apoptosis. The first stage of the elimination process is the internalization of the pathogens or apoptotic bodies into a plasma membrane-derived vacuole, known as phagosome ([Figure 1A and 1B](#ppat-1002729-g001){ref-type="fig"}). Newly formed phagosomes, however, lack the ability to kill pathogens or to degrade the ingested targets. These properties are acquired during the course of phagosome maturation when the phagosome membrane and contents undergo considerable remodeling to transform the initially inert environment into a microbicidal one. Phagosomes mature by sequential fusion with endocytic (early and late endosomes) and lysosomal compartments culminating with the formation of the phagolysosome ([Figure 1C](#ppat-1002729-g001){ref-type="fig"}), a highly acidic (pH between 4.0 and 5.0) compartment, in which the ingested pathogen is degraded (reviewed in [@ppat.1002729-Flannagan1], [@ppat.1002729-Kinchen1]).

![Ultrastructure of nascent phagosomes and phagolysosomes within phagocytic cells in a murine model of tuberculosis.\
(A) Nascent phagosomes containing phagocytosed mycobacteria (arrows) are seen in the cytoplasm of a neutrophil. In (B), macrophage pseudopods encircle an apoptotic cell (arrowheads). (C) Typical phagolysosomes (Ph) within a macrophage show heterogenous content and varying sizes and electron-density. A degenerating bacterium is observed (arrow). Mice were infected with *Mycobacterium bovis* bacillus Calmette-Guerin (BCG) and cells from the pleural cavity processed for transmission electron microscopy as before [@ppat.1002729-DAvila1]. Scale bars, 1 µm (A, B), 500 nm (C).](ppat.1002729.g001){#ppat-1002729-g001}

In cells from the immune system, mainly macrophages, both pathogen phagocytosis and progression of pathogen-containing phagosomes generally occurs in parallel with accentuated formation of lipid-rich organelles, termed lipid bodies (LBs) or lipid droplets [@ppat.1002729-DAvila1]--[@ppat.1002729-DAvila2]. These organelles, largely associated with lipid storage in the past, are now recognized as dynamic and functionally active organelles, involved in a variety of functions such as lipid metabolism, trafficking, and signaling. LBs have also attracted considerable attention due to their link with human diseases such as obesity, inflammatory diseases, and cancer (reviewed in [@ppat.1002729-Bozza1]--[@ppat.1002729-Farese1]). Experimental and clinical infections with different pathogens such as bacteria [@ppat.1002729-DAvila1], [@ppat.1002729-Peyron1], [@ppat.1002729-Mattos1]--[@ppat.1002729-Cao1], parasites [@ppat.1002729-Melo1]--[@ppat.1002729-DAvila2], [@ppat.1002729-Charron1], [@ppat.1002729-Magalhaes1], and viruses [@ppat.1002729-Barba1], [@ppat.1002729-Samsa1] induce LB accumulation within different cell types. One intriguing aspect of LBs formed in response to infections is the ability of these organelles to relocate in the cytoplasm and interact with phagosomes, suggesting a significant and yet ill-understood association between these structures [@ppat.1002729-DAvila1]--[@ppat.1002729-Melo2], [@ppat.1002729-Mattos2], [@ppat.1002729-Cocchiaro1]. This interaction occasioned attention because it may have implications for the microorganism outcome or survival within host cells. Here, we summarize our current knowledge on the LB-phagosome interaction within cells from the immune system, with emphasis on macrophages, key players in the initial resistance to the infection, and discuss the functional meaning of this event during infectious diseases.

LB Structure and Composition {#s2}
============================

LBs are intracellular organelles of all cell types including plants and microorganisms (reviewed in [@ppat.1002729-Murphy1]). Despite variations in function, appearance, and composition between different organisms and their cell types, all LBs are recognized by a distinctive architecture---the presence of a core containing neutral lipids mainly tryacylglycerols (TAG) and sterol esters (SE) surrounded by a phospholipid hemimembrane with associated proteins [@ppat.1002729-Murphy1], [@ppat.1002729-TauchiSato1]. Therefore, in contrast to all cytoplasmic organelles and vesicles that have an aqueous content surrounded by a phospholipid bilayer membrane, the LB surface lacks a delimiting unit membrane structure ([Figure 2](#ppat-1002729-g002){ref-type="fig"}). This unique feature of LBs facilitates the identification of these organelles by transmission electron microscopy (TEM) compared to other intracellular membranous organelles ([Figure 2](#ppat-1002729-g002){ref-type="fig"}) [@ppat.1002729-Melo2].

![Lipid body (LB) structure and composition.\
(Ai--Aiii) A LB within a human blood eosinophil is observed by transmission electron microscopy (TEM) at different magnifications (boxed area in Ai is shown in Aii and Aiii). LBs are delimited by a monolayer of phospholipids differing from the structural organization (phospholipid bilayer membrane) of all other organelles, vesicles, and plasma membrane (arrowheads in Aii and box in Aiii). Structural proteins from the perilipin family are associated with the LB surface while the LB core contains mainly sterol esters (SE), triacylglycerols (TAG), diacilglycerols (DAG), and cholesterol. Numerous proteins are frequently found in LBs such as Rab GTPases, lipid metabolism enzymes, kinases, caveolins, and chaperones. Nu, nucleus; Gr, secretory granule. Scale bar, 600 nm.](ppat.1002729.g002){#ppat-1002729-g002}

LBs contain a collection of proteins with numerous biological functions. LB-specific structural proteins, the PAT family of proteins (recently renamed to perilipin family proteins [@ppat.1002729-Kimmel1])---perilipin/PLIN1, adipose differentiation-related protein (ADRP/Adipophilin/PLIN2) [@ppat.1002729-Brasaemle1], and tail-interacting protein of 47 kDa (TIP47/PLIN3) [@ppat.1002729-Wolins1]---are constitutively associated with the circumferential rim of LBs ([Figure 2](#ppat-1002729-g002){ref-type="fig"}) and participate in the regulation of cellular lipid metabolism [@ppat.1002729-Bickel1]. Moreover, enzymes of lipid metabolism, membrane trafficking proteins including small GTPases of the Rab family (critical regulators of vesicular traffic and organelle interaction), endoplasmic reticulum (ER) proteins, and molecular chaperones are frequently identified in LB fractions ([Figure 2](#ppat-1002729-g002){ref-type="fig"}) [@ppat.1002729-Wan1]. In fact, a growing list of proteins, provided mainly by proteomic studies, has been described in association with LBs as summarized in several reviews [@ppat.1002729-Hodges1]--[@ppat.1002729-Goodman1]. The LB protein composition greatly varies depending on the cell type and its physiological state. Interestingly, LBs may act as platforms for managing the availability of proteins, functioning as transient sites for proteins that will be released, delivered, or destructed [@ppat.1002729-Welte1]. However, how proteins are specifically targeted to LBs is still poorly understood.

It has been recognized that proteins are not restricted to the LB surface, but they are also embedded in the LB core. For example, freeze-fracture immunocytochemistry and EM revealed that perilipin, caveolin-1, ADRP, and TIP47 are present in the LB cores of adipocytes and macrophages [@ppat.1002729-Robenek1]. How polar proteins such as TIP47 and ADRP are arranged within these organelles remains to be defined.

LB Composition in Cells from the Immune System {#s2a}
----------------------------------------------

As noted, LBs within a cell differ regarding function and metabolic status and these characteristics are reflected in their composition. In cells from the immune system, LBs are recognized as sites for generation of inflammatory mediators (eicosanoids) and therefore have specific molecules linked to this synthesis (reviewed in [@ppat.1002729-Bozza1], [@ppat.1002729-Melo3]).

LBs from macrophages, eosinophils, neutrophils, and mast cells contain stores of arachidonic acid (AA) associated with pools of phospholipid and/or neutral lipids [@ppat.1002729-Dvorak1]--[@ppat.1002729-Triggiani1]. AA is a 20-carbon fatty acid and a key signaling molecule acting as intracellular second messenger, as paracrine mediator of cell activation, and as a substrate for enzymatic conversion into eicosanoids [@ppat.1002729-Yaqoob1].

The major enzymes involved in the enzymatic conversion of AA into eicosanoids are also present within LBs from activated cells of the immune system, mainly macrophages, eosinophils, and neutrophils. These enzymes include cyclooxygenases (COX) [@ppat.1002729-DAvila1], [@ppat.1002729-DAvila2], [@ppat.1002729-Dvorak1], [@ppat.1002729-Dvorak2]--[@ppat.1002729-Bozza2], 5-and 15-lypoxygenases (5-LO and 15-LO) [@ppat.1002729-Bozza2], [@ppat.1002729-Bozza3], and leukotriene C~4~ (LTC~4~)-synthase [@ppat.1002729-Bozza2]. Moreover, phospholipase A~2~ (cPLA~2~) and its activating protein kinases, mitogen-activated protein (MAP) kinases (ERk1, ERK2, p85, and p38), the upstream involved in AA liberation, have been described within LBs [@ppat.1002729-Yu1].

Overall, LBs from cells of the immune system compartmentalize the substrate (AA) and the entire enzymatic machinery for eicosanoid synthesis. Because eicoisanoids are non-storable mediators, newly formed and rapidly released upon cell stimulation, the detection of these molecules is not simple. However, by means of a new strategy to cross-link newly formed eicosanoids at its sites of synthesis, the presence of eicosanoids has been directly demonstrated within LBs [@ppat.1002729-BandeiraMelo1]. prostaglandin E~2~ (PGE~2~) was found in LBs from mouse macrophages infected with *Mycobacterium bovis BCG*, which causes bovine tuberculosis [@ppat.1002729-DAvila1], or with the intracellular protozoan parasite *Trypanosoma cruzi*, the causal agent of Chagas\' disease, a debilitating cardiac illness [@ppat.1002729-DAvila2]; LTC~4~ was demonstrated in LBs from human eosinophils and basophils stimulated with the chemokines eotaxin/CCL11 and RANTES/CCL5 [@ppat.1002729-BandeiraMelo2] and in eosinophil LBs from murine models of allergic inflammation [@ppat.1002729-VieiradeAbreu1], and LTB~4~in LBs from neutrophils and macrophages during sepsis [@ppat.1002729-Pacheco1].

In summary, there is good evidence that LBs are able to change their composition in concert with cell activation acting as inflammatory organelles with roles in the innate immune response to infections and inflammatory processes.

Pathogen Induction of LB Formation {#s3}
==================================

Pathogens induce several changes in the host cell signaling and trafficking mechanisms. One prominent pathogen-mediated change is the formation of LBs in the host cell cytoplasm. Most cells contain a small number of cytoplasmic LBs, but they can be rapidly stimulated to form new LBs under interaction with pathogens. This interaction is also able to increase LB si*z*e and to induce LB ultrastructural alterations. LB biogenesis is a process that happens in vivo and in vitro in response to a variety of pathogens.

Parasites {#s3a}
---------

The first observation of newly formed LBs in response to an in vivo parasite infectious disease dates to 2003 [@ppat.1002729-Melo1]. By investigating inflammatory macrophages from rats infected with a virulent strain of *T. cruzi* (Y strain), a significant increase of the LB numbers in peritoneal macrophages at day 6 and 12 of the infection was found. While control peritoneal macrophages presented ∼2.19±0.4 (mean ± SEM) LBs/cell, peritoneal macrophages from infected animals showed ∼18.09±1.4 LBs/cell at day 12 of infection. At this time, the most intense inflammatory process and parasitism in the heart, a target organ of Chagas\' disease, compared to other points during the acute phase in rats, is observed [@ppat.1002729-Melo1]. Accordingly, inflammatory macrophages recruited to the heart exhibited a striking increase in LB numbers ([Figure 3](#ppat-1002729-g003){ref-type="fig"}) [@ppat.1002729-Melo1]. *T. cruzi* is also capable to induce in vitro LB formation within mouse peritoneal macrophages through a Toll-like receptor -2 (TLR2)-dependent mechanism [@ppat.1002729-DAvila2]. At 24 h of murine infection, both the cells containing internalized parasites as well non-parasitized cells showed an increased number of LBs compared to control, non-infected cells, suggesting a bystander amplification of the response [@ppat.1002729-DAvila2]. Interestingly, parasitized cells showed a significantly higher number of LBs (3-fold) compared to non-parasitized cells, demonstrating that the uptake of the parasite directly induces LB biogenesis [@ppat.1002729-DAvila2].

![Lipid bodies (LBs) increase in number and interact with phagosomes within heart inflammatory macrophages during parasite infection.\
LBs with different sizes are seen as electron-dense or electron-lucent organelles surrounding and in contact (arrow) with a large phagolysosome containing an intact amastigote (\*), the intracellular form of the parasite *Trypanosoma cruzi*. Rats were infected with the Y strain of *T. cruzi* and samples of the heart, a target organ of the parasite, processed for transmission electron microscopy at day 12 of infection [@ppat.1002729-Melo2], [@ppat.1002729-Fabrino1], [@ppat.1002729-Melo4]. Nu, nucleus. Scale bar, 800 nm.](ppat.1002729.g003){#ppat-1002729-g003}

Pathological studies of target organs of malaria, such as kidney and liver, found the presence of a high number of LBs in infected mice, indicating that the parasite *Plasmodium berghei*, the causative agent of the disease, induces LB accumulation in host cells [@ppat.1002729-RodriguezAcosta1], [@ppat.1002729-PulidoMendez1]. Other parasites such as *Toxoplasma gondii*, which causes human toxoplasmosis [@ppat.1002729-Charron1], and *Leishmania amazonensis*, a causal agent of human leishmaniasis [@ppat.1002729-Pinheiro1], trigger LB formation during the in vitro infection of human fibroblasts and mouse peritoneal macrophages, respectively.

Bacteria {#s3b}
--------

Interaction of pathogenic bacteria with host cells leads to LB biogenesis. Tuberculosis caused by *Mycobacterium tuberculosis* is characterized by a tight interplay between *M. tuberculosis* and host cells within cellular aggregates (granulomas) [@ppat.1002729-Peyron1], [@ppat.1002729-Cardona1]. The induction of foamy macrophages---a granuloma-specific cell population characterized by its high lipid content compartmentalized in LBs---has been extensively reported during the progression of tuberculosis caused by *M. tuberculosis* in both humans and experimental settings [@ppat.1002729-Peyron1], [@ppat.1002729-Daniel1], [@ppat.1002729-Cardona1]. In experimental studies with *Mycobacterium bovis* bacillus Calmette-Guerin (BCG), it was found that this pathogen is capable of inducing a dose- and time-dependent increase on LB formation within pleural macrophages [@ppat.1002729-DAvila1]. LB formation initiates rapidly and significantly increased LB numbers are noted within 1 h, reaching maximum levels within 24 h, and remaining increased for at least 15 d after BCG infection [@ppat.1002729-DAvila1]. Remarkably, nonsteroidal anti-inflammatory drugs (NSADs), such as aspirin and NS-398, drastically inhibited *M. bovis BCG*-induced LB formation within 24 h. In parallel, the BCG-induced PGE~2~ generation was completely abrogated [@ppat.1002729-DAvila1].

Accumulation of lipid-filled foamy macrophages is also a hallmark of lepromatous leprosy, a chronic disease caused by *Mycobacterium leprae*. Leprosy is characterized by widespread skin lesions in which *M. leprae* lives and replicates in foamy macrophages. These macrophages are highly positive for ADRP [@ppat.1002729-Mattos1], [@ppat.1002729-Tanigawa1] and perilipin [@ppat.1002729-Tanigawa1]. Moreover, *M. leprae* infection increases expression of ADRP/perilipin mRNA in THP-1 cells, a human promonocytic cell line [@ppat.1002729-Tanigawa1]. These observations indicate that the foamy aspect of macrophages is derived from LB accumulation induced during *M. leprae* infection. In fact, the capacity of *M. leprae* to induce LB formation was confirmed in vivo via an experimental model of mouse pleurisy and in in vitro studies with human monocytes and murine peritoneal macrophages [@ppat.1002729-Mattos1].

LB formation within macrophages is also driven by infection with *Chlamydia pneumonia* and characterizes the early atherosclerosis in the presence of low-density lipoprotein (LDL) [@ppat.1002729-Cao1]. More recently, an in vivo ultrastructural study during the initial infection with *Chlamydia muridarum,* which causes genital infection in mice, demonstrated that epithelial host cells accumulate LBs in parallel to bacteria replication [@ppat.1002729-Rank1].

Interestingly, the bacterium uptake does not seem essential for LB formation within macrophages and other cells. In human peripheral blood monocytes and murine macrophages exposed to *M. leprae*, LB biogenesis is observed in the cytoplasm of both cells bearing bacteria and cells with no bacteria [@ppat.1002729-Mattos1]. However, as noted in macrophages cultured with T. *cruzi* [@ppat.1002729-DAvila2], cells with internalized pathogens showed higher LB formation compared to cells that were exposed to the pathogens but did not engulf them [@ppat.1002729-Mattos1], indicating that phagocytosis potentiates LB biogenesis.

Bacterial derivates such as lipopolysaccharide (LPS) present in all Gram-negative bacteria [@ppat.1002729-Cao1], [@ppat.1002729-Pacheco2] and the mycobacterial cell wall component lipoarabinomannan (LAM), a virulence factor of *M. tuberculosis* [@ppat.1002729-DAvila1], are also able to induce LB formation in macrophages.

Distinct signaling pathways can trigger LB formation within cells from the immune system. Specific bacteria- and receptor-mediated pathways activate intracellular signaling that leads to enhanced LB formation. For instance, *M. bovis* BCG [@ppat.1002729-DAvila1], but not the non-pathogenic bacteria *Mycobacterium smegmatis* or *Bacillus subtilis* [@ppat.1002729-DAvila1], induces toll-like receptor 2 (TLR2)-mediated formation of LBs in macrophages; TLR6 but not TLR2 drives LB biogenesis in *M. leprae*-infected Schwann cells [@ppat.1002729-Mattos3], and TLR2 but not TLR4 are involved in the formation of LBs in macrophages infected with *Chlamydia pneumonia* [@ppat.1002729-Cao1].

Viruses {#s3c}
-------

LB formation is also induced by infection with viruses such as the hepatitis C virus (HCV), the major causative pathogen associated with liver cirrhosis and hepatocellular carcinoma [@ppat.1002729-Barba1], and dengue virus (DENV), an emerging viral disease transmitted by arthropods to humans in tropical countries [@ppat.1002729-Samsa1]. Pharmacological inhibition of LB formation greatly decreases DENV and HCV replication [@ppat.1002729-Samsa1], [@ppat.1002729-McLauchlan1], suggesting LBs as targets for antiviral strategies.

A list of pathogens that induce LB biogenesis within different mammalian cells is shown in [Table 1](#ppat-1002729-t001){ref-type="table"}.

10.1371/journal.ppat.1002729.t001

###### Pathogen-induced lipid body (LB) formation and LB-phagosome interaction in mammalian cells.

![](ppat.1002729.t001){#ppat-1002729-t001-1}

  Pathogen                           LB Formation   LB-Phagosome Interaction               Cell Type               Organism                                     Refs
  --------------------------------- -------------- -------------------------- ----------------------------------- ---------- ---------------------------------------------------------------------------
  **Bacteria**                                                                                                               
  *Acinetobacter baumannii*               \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Bacillus subtilis*                     −                    −                          Macrophages               Mouse                              [@ppat.1002729-DAvila1]
  *Chlamydia muridarum*                   \+                   \+                  Epithelial cells (cervix)        Mouse                               [@ppat.1002729-Rank1]
  *Chlamydia pneumoniae*                  \+                  n.d.                        Macrophages               Mouse                               [@ppat.1002729-Cao1]
  *Chlamydia trachomatis*                 \+                   \+                       Hep2 cell line              Human                              [@ppat.1002729-Kumar1]
                                          \+                   \+                       HeLa cell line              Human                            [@ppat.1002729-Cocchiaro1]
  *Escherichia coli*                     n.d.                  \+              THP-1 cell line (macrophage-like)    Human                               [@ppat.1002729-Luo1]
                                          \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Klebsiella pneumonia*                  \+                  n.d.                Peripheral blood monocytes        Human                             [@ppat.1002729-Nicolaou1]
                                          \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Mycobacterium bovis* BCG               \+                   \+                     Pleural macrophages           Mouse                              [@ppat.1002729-DAvila1]
  *Mycobacterium leprae*                  \+                  n.d.                     Skin macrophages             Human                              [@ppat.1002729-Mattos1]
                                          \+                  n.d.                Peripheral blood monocytes        Human                              [@ppat.1002729-Mattos1]
                                          \+                  n.d.                  Peritoneal macrophages          Mouse                              [@ppat.1002729-Mattos1]
                                          \+                  n.d.                    Pleural macrophages           Mouse                              [@ppat.1002729-Mattos1]
                                          \+                   \+                        Schwann cells              Human                              [@ppat.1002729-Mattos2]
  *Mycobacterium smegmatis*               −                    −                          Macrophages               Mouse                              [@ppat.1002729-DAvila1]
  *Mycobacterium tuberculosis*            \+                   \+                Foamy macrophages (granuloma)      Human                              [@ppat.1002729-Peyron1]
                                          \+                  n.d.                        Macrophages               Human                              [@ppat.1002729-Daniel1]
  *Proteus vulgaris*                      \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Pseudomonas aeruginosa*                \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Pseudomonas diminuta*                  \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Staphylococcus aureus*                 \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Staphylococcus epidermidis*            \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Staphylococcus salivarius*             \+                  n.d.                Peripheral blood monocytes        Human                             [@ppat.1002729-Nicolaou1]
                                          \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  *Vibrio cholera*                        \+                  n.d.                    Mucosal mast cells            Human                              [@ppat.1002729-Qadri1]
  **Bacteria Derivates**                                                                                                     
  CpG-DNA                                 \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  Flagellin                               \+                  n.d.                     J774 macrophages             Mouse                             [@ppat.1002729-Nicolaou1]
  LPS (lipopolysaccharide)                \+                  n.d.                        Macrophages               Mouse     [@ppat.1002729-Cao1], [@ppat.1002729-Pacheco2], [@ppat.1002729-Nicolaou1]
  LAM (lipoarabinomannan)                 \+                  n.d.                        Macrophages               Mouse                              [@ppat.1002729-DAvila1]
  **Parasites**                                                                                                              
  *Leishmania amazonensis*                \+                  n.d.                  Peritoneal macrophages          Mouse                             [@ppat.1002729-Pinheiro1]
  *Plasmodium berghei*                    \+                  n.d.                       Kidney cells               Mouse                           [@ppat.1002729-PulidoMendez1]
                                          \+                  n.d.                        Liver cells               Mouse                         [@ppat.1002729-RodriguezAcosta1]
  *Schistosoma mansoni* derivates         \+                  n.d.                        Eosinophils               Mouse                            [@ppat.1002729-Magalhaes1]
  *Toxoplasma gondii*                     \+                  n.d.                        Fibroblasts               Human                             [@ppat.1002729-Charron1]
  *Trypanosoma cruzi*                     \+                   \+                      Heart macrophages             Rat                    [@ppat.1002729-Melo1], [@ppat.1002729-Melo2]
                                          \+                   \+                   Peritoneal macrophages           Rat                    [@ppat.1002729-Melo1], [@ppat.1002729-Melo2]
                                          \+                  n.d.                  Peritoneal macrophages          Mouse                              [@ppat.1002729-DAvila2]
  **Viruses**                                                                                                                
  *Dengue virus*                          \+                  n.a.                       BHK-21 cells              Hamster                             [@ppat.1002729-Samsa1]
  *Hepatitis C virus*                     \+                  n.a.                 CHO and HepG2 cell lines         Human                              [@ppat.1002729-Barba1]
  **Fungi**                                                                                                                  
  *Candida albicans* derivates            \+                  n.d.                        Macrophages                Rat                               [@ppat.1002729-Paraje1]
                                          \+                  n.d.                        Hepatocytes                Rat                               [@ppat.1002729-Paraje1]

+, induced; −, not induced; n.d., not determined; n.a., not applicable.

Pathogen-Mediated LB Structural Changes {#s3d}
---------------------------------------

Newly formed LBs within pathogen-infected macrophages can show changes in si*z*e and ultrastructure. In scoring the diameters of LBs within inflammatory macrophages from rats experimentally infected with *T. cruzi*, 74% of LBs had a size \<0.5 µm in non-infected whereas 54% of LBs from infected animals were \>0.5 µm, reaching up to 3 µm. When macrophages from *T. cruzi*-infected animals were challenged in vivo with higher parasite load, a significant increase of LB sizes compared to LBs induced by the infection alone was observed [@ppat.1002729-Melo2].

One interesting ultrastructural aspect of LBs is their electron-density (osmiophilia), which is dependent on the cell type and can change in response to pathogens. When observed by TEM, macrophages from mice infected with *M. bovis* BCG show distinct morphology, becoming larger and less dense organelles compared to LBs from non-infected cells [@ppat.1002729-DAvila1]. Accordingly, LBs formed in response to the in vivo *T. cruzi* infection within inflammatory macrophages also exhibited changes in electron-density compared to uninfected cells [@ppat.1002729-Melo2]. Interestingly, LBs change their electron-density in macrophages stimulated in vivo with higher parasite load. Rats were exposed to a single, high dose of gamma irradiation 1 d before infection, which depletes the humoral and cellular immune responses except for the phagocytic activity of macrophages. Inflammatory macrophages from irradiated-infected animals showed an increase in the numbers of both light-dense and strongly electron-dense LBs compared to infection alone [@ppat.1002729-Melo2]. Pathogen-mediated LB morphological changes may reflect differences in lipid or protein composition, stages of formation of new LBs, mobilization, and/or neutral lipids/phospholipids ratio within LBs [@ppat.1002729-Melo2].

Interaction of LBs with Phagosomes {#s4}
==================================

The first documentation of a significant interaction between LBs and phagosomes dates to 1983 [@ppat.1002729-Dvorak4]. In an autoradiographic ultrastructural study of the incorporation of ^3^H AA by macrophages that were also exposed to zymosan particles for phagocytosis, a striking approximation of ^3^H AA-incorporated LBs with phagolysosomes was observed ([Figure 4](#ppat-1002729-g004){ref-type="fig"}). Moreover, ^3^H AA-labeled LBs occasionally fused with phagolysosomes membranes and many cells exhibited autoradiographic grains over phagolysosomes ([Figure 4](#ppat-1002729-g004){ref-type="fig"}) [@ppat.1002729-Dvorak4]. This was the first evidence that LBs not only were able to associate with phagosomes but also discharged their contents into these structures [@ppat.1002729-Dvorak4]. However, this interaction received scant attention for two decades.

![Human lipid bodies (LBs) observed with an ultrastructural method for autoradiography after a pulse of tritiated arachidonic acid and exposure to zymosan.\
(A) ^3^H-arachidonate incorporated by a human macrophage is localized predominantly in LBs in association with zymosan-filled phagosomes. In (B), a LB labeled with numerous silver grains is seen in higher magnification. Note that the labeled lipid content is projecting into the zymosan-containing phagosome lumen. Scale bars, 1 µm (A), 600 nm (B).](ppat.1002729.g004){#ppat-1002729-g004}

In 2003, a study of inflammatory macrophages triggered by the in vivo infection with *T. cruzi* demonstrated a clear association of LBs with phagosomes in parallel to LB formation ([Figures 3](#ppat-1002729-g003){ref-type="fig"} and [5](#ppat-1002729-g005){ref-type="fig"}) [@ppat.1002729-Melo1]. Detailed quantitative TEM analyses of the LB-phagosome interaction induced by the experimental *T. cruzi* infection revealed that 47% of newly formed LBs were associated with phagolysosomes within inflammatory macrophages, mainly in the heart. LBs were seen surrounding or attached to phagosomes ([Figures 3](#ppat-1002729-g003){ref-type="fig"} and [5](#ppat-1002729-g005){ref-type="fig"}) and even within the lumen of these structures ([Figure 5](#ppat-1002729-g005){ref-type="fig"}), indicating that the LB-phagosome interaction can result in LB internalization into parasite-containing phagosomes [@ppat.1002729-Melo2]. Later the identification by TEM of LB-phagosome interaction in macrophages from both animal models and humans infected with mycobacteria brought new attention to LBs as organelles connected with the life cycle of pathogens [@ppat.1002729-DAvila1], [@ppat.1002729-Peyron1].

![Lipid bodies (LBs) translocate to phagolysosomes in infected macrophages.\
(Ai) LBs with different electron-densities are observed around a large phagolysosome (outlined in red in Aii) in the macrophage cytoplasm. Note that several LBs (highlighted in yellow in Aii) are seen within the phagolysosome. Rats were infected with the Y strain of *T. cruzi* and heart samples processed for transmission electron microscopy at day 12 of infection [@ppat.1002729-Melo2], [@ppat.1002729-Fabrino1], [@ppat.1002729-Melo4]. Nu, nucleus. Scale bar, 600 nm.](ppat.1002729.g005){#ppat-1002729-g005}

Other studies have been demonstrating LB translocation into the lumen of bacteria-containing phagosomes using live cell fluorescence microscopy and/or TEM [@ppat.1002729-Mattos2], [@ppat.1002729-Cocchiaro1], [@ppat.1002729-Rank1]. In an experimental model of infection with the intracellular pathogen *Chlamydia trachomatis*, which causes several ailments such as trachoma, conjunctivitis, epididymitis, and pelvic inflammatory disease, it was shown that LBs dock at the surface of the bacteria-containing vacuole (termed "inclusions") within Hep2 or HeLa cells, penetrate the vacuole membrane, and intimately associate with reticulate bodies, the replicative form of *Chlamydia* [@ppat.1002729-Cocchiaro1], [@ppat.1002729-Kumar1].

Nerve biopsies of patients infected with *M. leprae* also show accumulating LBs in close association with *M. leprae*-containing phagosomes within Schwann cells, a target cell of this pathogen. These LBs are then promptly recruited to the bacteria-containing phagosomes, a process that depends on cytoskeletal reorganization and phosphatidylinositol 3 kinase (PI3K) signaling [@ppat.1002729-Mattos2]. Thus, the lipid-laden, bacterial-bearing vacuoles observed in heavily infected SCs in lepromatous leprosy nerve biopsies might be formed by the continuous formation and recruitment of LBs, giving rise to their foamy appearance [@ppat.1002729-Mattos2]. Another in vivo study using a model of intracervical murine infection with *Chlamydia muridarum* demonstrated the same phenomenon---multiple LBs in contact with the pathogen-containing vacuole and LBs entering into the vacuole within host cells [@ppat.1002729-Rank1].

Overall, infection with different pathogens leads to movement of LBs into phagosomes. It is intriguing how pathogens target LB and how intact and non-membrane-bound organelles such as LBs are translocated across the phagosome membrane. Bacterial proteins seem to be involved in capturing LB into bacteria-containing vacuoles while the translocation process seems to involve displacement of the LB structural protein ADRP from the LB surface to the phagosome membrane, as observed during the in vitro infection with *Chlamydia trachomatis* [@ppat.1002729-Cocchiaro1]. Interestingly, both ADRP and perilipin, were also immunolocalized on the membranes of bacilli-containing phagosomes in macrophages from skin biopsy specimens from patients with lepromatous leprosy [@ppat.1002729-Tanigawa1]. However, the mechanistic details underlying the LB-phagosome interaction require further investigations to be deciphered.

LB-phagosome association has also been observed in other situations. Contact sites between LBs and latex bead-containing phagosomes were identified by high resolution Raman microscopy in neutrophilic granulocytes [@ppat.1002729-vanManen1] and by fluorescence microscopy in dendritic cells [@ppat.1002729-Bougneres1]. By using time-lapse fluorescence microscopy, it was pointed out that the LB-phagosome association within neutrophilic granulocytes seems transient, similar to "kiss-and-run" behavior displayed by endosomes involved in phagosome maturation [@ppat.1002729-vanManen1]. LBs were also observed in close contact with nascent autophagosomes within normal rat kidney (NRK) cells [@ppat.1002729-YlaAnttila1], but the biology of LBs during autophagy is still not understood.

LB-Phagosome Interaction: Functional Implications {#s5}
=================================================

As noted, the LB-phagosome interaction seems to be a general event found during infections with different pathogens in both humans and experimental models. Although little is known about the functional meaning of this interaction, it raises intriguing possibilities in light of the LB composition and functions.

Much interest has been focused on LBs as conduits for the transport of potential nutrients, especially neutral lipids, to the phagosome. The lipid content of LBs may, therefore, serve as a nutrient source for the pathogen enabling its survival within the cell [@ppat.1002729-DAvila1], [@ppat.1002729-Peyron1], [@ppat.1002729-Mattos2], [@ppat.1002729-Cocchiaro1], [@ppat.1002729-Mattos3]. The LB-phagosome interaction has been considered as a pathogen strategy for accessing host lipids during *M. tuberculosis* [@ppat.1002729-Peyron1] and *M. leprae* [@ppat.1002729-Mattos2] human infections and experimental infection with *Chlamydia trachomatis* [@ppat.1002729-Cocchiaro1]. Considering that *M. tuberculosis* bacilli are able to accumulate lipids during dormancy from which it derives both carbon and energy for its own metabolism [@ppat.1002729-Pandey1], the mycobacteria-phagosome interaction could be important for the pathogen growth and persistence [@ppat.1002729-DAvila1], [@ppat.1002729-Peyron1].

Pharmacological inhibition of LB formation within pathogen-infected cells was investigated. Using triacsin C, which prevents LD biogenesis by specifically inhibiting the activity of a subset of long chain acyl-coA synthetases (ACSL) required for triacylglyceride and cholesterol ester biosynthesis, a decrease was observed in the phagosome size and reduction of chlamydial growth within Hep2 cells [@ppat.1002729-Kumar1]. The use of another inhibitor of lipid metabolism, C75, which inhibits fatty acid synthase (FAS), inhibited not only the *M. tuberculosis*-induced LB formation but also the bacterial viability in Schwann cells [@ppat.1002729-Mattos3].

The possibility of LBs to deliver other nutrients into the phagosome for pathogen growth was also raised. Complexes of iron and mycobactins, lipophilic siderophores of mycobacteria, accumulate in LBs within macrophages infected with *Escherichia coli* [@ppat.1002729-Luo1]. It is suggested that a subsequent migration of iron-mycobactin complex from LBs to phagosomes would facilitate iron delivery to phagosomal mycobacteria, acting as an iron source for the pathogen and consequently promoting their growth [@ppat.1002729-Luo1].

Taken together, a picture emerges in which pathogens usurp host, newly-formed LBs to obtain nutrients, mainly lipids, as a survival strategy. Moreover, the enhanced capacity of host cells to generate inflammatory mediators in the course of pathogenic infections due to increased LB formation and compartmentalization of signaling and eicosanoid production within LBs may also be contributing to mechanisms that intracellular pathogens have developed to survive in host cells. For example, high concentration of PGE~2~ in macrophages act as a potent inhibitor of Th1 type response [@ppat.1002729-Renz1] and of nitric oxide (NO) production [@ppat.1002729-FreiredeLima1], creating thus an appropriate environment for optimal pathogen growth [@ppat.1002729-FreiredeLima1].

On the other hand, lipids have been gaining attention as co-directors of phagocytosis (reviewed in [@ppat.1002729-Steinberg1]). Lipids play multiple roles as determinants of phagosomal formation and fate and as coordinators of the recruitment and retention of key phagocytic proteins [@ppat.1002729-Steinberg1]. In *M. tuberculosis*-infected macrophages, selected lipids, including AA, can activate actin assembly, phagosome-lysosome fusion, and phagosome maturation, resulting in bacteria killing [@ppat.1002729-Anes1]. Lipids also help to activate the phagosome-resident enzyme nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase [@ppat.1002729-Suh1], an event essential for the degradation of microbes upon infection [@ppat.1002729-Flannagan1]. Because several subunits of NADPH oxidase depend on AA, it was suggested that the AA content of LBs are used by phagocytes to locally activate NADPH-oxidase [@ppat.1002729-vanManen1].

Key molecules, such as Rab 5 and Rab 7, are involved in the sequential interactions of early and late endosomes with phagosomes [@ppat.1002729-Flannagan1], [@ppat.1002729-Kinchen1]. Considering that LBs are sites for these GTPases ([Figure 2](#ppat-1002729-g002){ref-type="fig"}) [@ppat.1002729-Wan1], [@ppat.1002729-Liu1], the association of LBs with phagosomes may constitute a mechanism for Rab transport to and from the phagosome for phagosome maturation [@ppat.1002729-vanManen1]. Igtp (Irgm^3^), an ER-resident 47 KDa immune-related GTPase involved in phagosomal maturation and phagocytic cross-presentation, was also identified in LBs within dendritic cells, indicating that LBs regulate cross-presentation of phagocytosed antigens in these cells [@ppat.1002729-Bougneres1]. In addition, the presence of contact sites between LBs and phagosomes in dendritic cells may support a regulatory function of LBs on phagolysosomal progression [@ppat.1002729-Bougneres1]. Thus, the enigmatic LB-phagosome interaction cannot be solely viewed as a pathogen strategy to prolong and sustain its own survival, but also might be a host strategy to destroy or, at least, to "try" to kill the microbial invader.

Summary and Perspectives {#s6}
========================

LBs emerge as key organelles involved in experimental and clinical infections with different pathogens, such as bacteria, parasites, and viruses. Within cells recruited in response to these infections, especially macrophages, LBs contribute to the genesis of inflammatory mediators and are considered as structural markers of inflammation. In addition to LB accumulation, interaction of these organelles with pathogen-containing phagosomes has increasingly been recognized. Recent observations have indicated that this intriguing and intimate association is a pathogen-driven process, evolved as a strategy to survive within the host cells by sequestering mainly host lipids. However, it should be noted that the LB-phagosome interaction may be linked to defense events in which the host cell seeks to kill the pathogen invader. Because phagosomal membrane and luminal contents must undergo remodeling to transform the initially inert environment into a microbicidal one, attention should be paid to LBs as potential determinant organelles in the phagocytic event. While this is more speculative, to date we cannot answer whether LBs have a major and a definitive role in the intracellular survival or destruction of pathogens and/or if these organelles are able to interfere with phagocytosis pathways. Other questions regarding how pathogens target LBs and/or how LBs target pathogen-containing phagosomes and are translocated into these vaccuoles await a lot of more investigations. Novel approaches such as electron tomographic analysis of the LB-phagosome interaction dynamics combined with further refined functional analyses will be required to address these questions. A better understanding of the cell biology of LBs and their potential role during pathogen phagocytosis may be crucial for the application of novel therapies addressing different pathological conditions.

![Schematic representation of pathogen-mediated LB formation, LB translocation to phagosomes, and possible consequences of the LB-phagosome interaction.\
Different pathogens induce LB formation within infected cells, such as macrophages. LB biogenesis occurs after both cell exposition to pathogens and/or receptor-mediated pathogen uptake. Cytoplasmic newly formed LBs relocate in the cytoplasm, dock at the surface of pathogen-containing phagosomes, and translocate into their lumen. This interaction may enable acquisition of nutrients for pathogen survival and multiplication or may be linked to host cell defense mechanisms favoring phagosome maturation and pathogen killing. Within macrophages and other inflammatory cells, LBs actively produce eicosanoids, such as prostaglandin E~2~ (PGE~2~), which may also contribute to pathogen outcome by inhibiting Th1 responses.](ppat.1002729.g006){#ppat-1002729-g006}
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